JP2019085364A5 - - Google Patents

Download PDF

Info

Publication number
JP2019085364A5
JP2019085364A5 JP2017214460A JP2017214460A JP2019085364A5 JP 2019085364 A5 JP2019085364 A5 JP 2019085364A5 JP 2017214460 A JP2017214460 A JP 2017214460A JP 2017214460 A JP2017214460 A JP 2017214460A JP 2019085364 A5 JP2019085364 A5 JP 2019085364A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
mitochondrial
compound represented
active ingredient
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017214460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019085364A (ja
JP6958860B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from JP2017214460A external-priority patent/JP6958860B2/ja
Priority to JP2017214460A priority Critical patent/JP6958860B2/ja
Priority to EP18876309.8A priority patent/EP3708161A4/en
Priority to PCT/JP2018/041354 priority patent/WO2019093379A1/ja
Priority to CN201880085315.7A priority patent/CN111556750B/zh
Priority to US16/759,486 priority patent/US11369615B2/en
Publication of JP2019085364A publication Critical patent/JP2019085364A/ja
Publication of JP2019085364A5 publication Critical patent/JP2019085364A5/ja
Publication of JP6958860B2 publication Critical patent/JP6958860B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017214460A 2017-11-07 2017-11-07 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途 Active JP6958860B2 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2017214460A JP6958860B2 (ja) 2017-11-07 2017-11-07 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
US16/759,486 US11369615B2 (en) 2017-11-07 2018-11-07 Agent for improving mitochondrial dysfunction, preventative or therapeutic agent for diseases or symptoms caused by mitochondrial dysfunction, and applications therefor
PCT/JP2018/041354 WO2019093379A1 (ja) 2017-11-07 2018-11-07 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
CN201880085315.7A CN111556750B (zh) 2017-11-07 2018-11-07 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途
EP18876309.8A EP3708161A4 (en) 2017-11-07 2018-11-07 MITOCHONDRIAL DYSFUNCTION IMPROVEMENT AGENTS, PROPHYLACTIC OR THERAPEUTIC FOR DISEASES OR SYMPTOMS CAUSED BY MITOCHONDRIAL DYSFUNCTION AND USES THEREFORE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017214460A JP6958860B2 (ja) 2017-11-07 2017-11-07 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途

Publications (3)

Publication Number Publication Date
JP2019085364A JP2019085364A (ja) 2019-06-06
JP2019085364A5 true JP2019085364A5 (US07794700-20100914-C00152.png) 2020-11-26
JP6958860B2 JP6958860B2 (ja) 2021-11-02

Family

ID=66437831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017214460A Active JP6958860B2 (ja) 2017-11-07 2017-11-07 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途

Country Status (5)

Country Link
US (1) US11369615B2 (US07794700-20100914-C00152.png)
EP (1) EP3708161A4 (US07794700-20100914-C00152.png)
JP (1) JP6958860B2 (US07794700-20100914-C00152.png)
CN (1) CN111556750B (US07794700-20100914-C00152.png)
WO (1) WO2019093379A1 (US07794700-20100914-C00152.png)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7265926B2 (ja) 2019-04-26 2023-04-27 株式会社Nttドコモ 通信制御装置および通信制御方法
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
JP7360229B2 (ja) 2021-11-15 2023-10-12 学校法人自治医科大学 フェロトーシス阻害剤及びその用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56166116A (en) * 1980-05-26 1981-12-21 Showa Denko Kk Carcinostatic agent
EP1210596A2 (en) 1999-06-22 2002-06-05 Mitokor Methods for assaying subcellular conditions using energy transfer
HU228783B1 (en) 2001-07-26 2013-05-28 Greenearth Cleaning Dry cleaning apparatus and method capable of utilizing a siloxane solvent
EP3144009A1 (en) * 2003-02-04 2017-03-22 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
JP2012529432A (ja) * 2009-06-05 2012-11-22 リンク・メディスン・コーポレーション アミノピロリジノン誘導体及びその使用
PT2952191T (pt) * 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
JP2012041314A (ja) * 2010-08-22 2012-03-01 Kanazawa Univ 脳腫瘍治療用キット及び脳腫瘍治療方法
US9283230B2 (en) 2011-02-11 2016-03-15 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
CA2865316A1 (en) * 2011-04-28 2012-11-01 Gino Cortopassi Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
JP6069321B2 (ja) * 2011-08-02 2017-02-01 ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハーHelmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt Gmbh フェノチアジン誘導体によるmalt1プロテアーゼの選択的阻害
US20140275045A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
CA2939219C (en) * 2014-02-11 2023-02-28 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
CA2920272A1 (en) * 2015-02-13 2016-08-13 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof to treat and prevent mitochondrial diseases and conditions
JP6763691B2 (ja) 2016-05-30 2020-09-30 上野製薬株式会社 熱可塑性樹脂組成物

Similar Documents

Publication Publication Date Title
JP2017531619A5 (US07794700-20100914-C00152.png)
JP2023002662A5 (US07794700-20100914-C00152.png)
JP2020097577A5 (US07794700-20100914-C00152.png)
JP2019510027A5 (US07794700-20100914-C00152.png)
JP2021063088A5 (US07794700-20100914-C00152.png)
RU2018133298A (ru) Способы применения агонистов fxr
JP2017141277A5 (US07794700-20100914-C00152.png)
JP2010077141A5 (US07794700-20100914-C00152.png)
JP2020507589A5 (US07794700-20100914-C00152.png)
JP2019510034A5 (US07794700-20100914-C00152.png)
JP2020023574A5 (ja) 近視予防、治療又は抑制用点眼剤、及び、小胞体ストレス抑制用点眼剤
JP2019085364A5 (US07794700-20100914-C00152.png)
JP2011527299A5 (US07794700-20100914-C00152.png)
JP2017526716A5 (US07794700-20100914-C00152.png)
JP2019516739A5 (US07794700-20100914-C00152.png)
JP2015510916A5 (US07794700-20100914-C00152.png)
JP2018529742A5 (US07794700-20100914-C00152.png)
JP2015516427A5 (US07794700-20100914-C00152.png)
JP2016510326A5 (US07794700-20100914-C00152.png)
JP2020523327A5 (US07794700-20100914-C00152.png)
JP2013508282A (ja) ウイルス感染のための併用療法処置
JP2017522300A5 (US07794700-20100914-C00152.png)
JP2015516419A5 (US07794700-20100914-C00152.png)
RU2007132971A (ru) Способы и материалы с транс-кломифеном для лечения мужского бесплодия
JP2017515840A5 (US07794700-20100914-C00152.png)